Active

Abingworth

Investor type

VC

Founded

2007

AUM

$2 000 M

Location

London, England, United Kingdom

Investment Ticket

$0-1 m

Investment Stage

Seed Series B Series A

Region of investment

North America Europe
Investor profile last updated: 25 April, 2025

Profile

Vast experience: check. Deep expertise: check. Easy accessibility: check. After decades of investing from offices in the most important centers of biotechnology worldwide, Abingworth offers entrepreneurs an unmatched combination of all three of these key attributes.

We partner with entrepreneurs to create companies that have a significant impact on patients’ lives. Participating at all stages of development and across all sectors, we take a broad strategic approach to investing in life sciences.

BROAD STRATEGIC APPROACH
Within the life sciences market we participate in a wide range of opportunities spanning therapeutics, medical devices, diagnostics, instrumentation and software. We invest in seed stage projects, technology platforms, preclinical and clinical assets as well as approved and marketed products. Supporting private and public companies, we aim to partner with the most innovative entrepreneurs to address significant unmet needs in healthcare.

Vast experience: check. Deep expertise: check. Easy accessibility: check. After decades of investing from offices in the most important centers of biotechnology worldwide, Abingworth offers entrepreneurs an unmatched combination of all three of these key attributes.

We can help attract talent for boards and leadership teams, choose drug targets for novel platforms, devise plans for clinical development, navigate legal issues, advise on PR strategy and think through corporate development and exit strategies. Adding to our own knowledge, we have a wide network of leading scientific and industry experts. Our collective experience is offered to all portfolio companies.

Industry

Pharmaceuticals Medical Devices Biotechnology Healthcare Services HealthTech Software AI MedTech Technology Life Sciences Machine Learning (ML) Fintech

Abingworth Funds

Name Type
Questionare
Industry
Questionare
Stage
Questionare
Region
Size AUM Launch date
Abingworth Clinical Co-Development Fund
Venture Capital (VC)
Biotechnology
Technology
Life Sciences
Pre-seed
Seed
Series A
North America
Europe
$5-10 m
$105 M
January 2016
Fund VII
Venture Capital (VC)
Healthcare Services
Technology
Life Sciences
Pre-seed
Seed
Series A
North America
Europe
$5-10 m
$220 M
August 2017
Abingworth Bioventures VII
Venture Capital (VC)
Biotechnology
Healthcare Services
Pharmaceuticals
Life Sciences
Seed
Series A
North America
Europe
$5-10 m
$315 M
July 2018
Abingworth Bioventures VIII
Venture Capital (VC)
Biotechnology
Healthcare Services
Pharmaceuticals
Technology
Life Sciences
Pre-seed
Seed
Series A
North America
Europe
$5-10 m
$465 M
February 2021
Abingworth Clinical Co-Development Co-Investment Fund
Venture Capital (VC)
Biotechnology
Fintech
Healthcare Services
Life Sciences
Pre-seed
Seed
Series A
North America
Europe
$5-10 m
$356 M
October 2023

Contacts

Name
Title
Email
avatar
Bali Muralidhar Managing Partner
Managing Partner
m•••@•••
avatar
Jacqueline Grant Principal
Principal
g•••@•••
Upgrade to see contacts
avatar
8tXIhinKCv1xcJNd 8tXIhinKCv1xcJNd
8tXIhinKCv1xcJNd
avatar
8tXIhinKCv1xcJNd 8tXIhinKCv1xcJNd
8tXIhinKCv1xcJNd
avatar
8tXIhinKCv1xcJNd 8tXIhinKCv1xcJNd
8tXIhinKCv1xcJNd
Investment-team contacts for Abingworth — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about Abingworth

Abingworth is a venture capital firm. It backs companies at Seed, Series B and Series A, writing tickets of $0-1 m.
Abingworth is located in London, England, United Kingdom.
Abingworth was founded in 2007.
Abingworth invests in companies and startups in Pharmaceuticals, Medical Devices, Biotechnology, Healthcare Services, HealthTech, Software, AI, MedTech, Technology, Life Sciences, Machine Learning (ML), Fintech.
Abingworth invests in companies and startups in North America, Europe.
Abingworth invests in companies and startups at Seed, Series B, Series A.
Abingworth usually invests $0-1 m on average.
Abingworth has around $2 000m assets under management.
Abingworth last fund was created/launched in 2023-10-23
Abingworth can be reached through its website abingworth.com, its LinkedIn page and its X account. Its general enquiries address is info@abingworth.com. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for Abingworth — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query Abingworth directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 25 April, 2025. Something out of date here? Report it — we re-run that firm within 48h and get back to you.